Oncolytic virus

Show results for

Unknown (1709)
Genomics (175)
Transcriptomics (143)
Proteomics (29)
Models (15)
Clinical (7)
Other (6)
Methylation profiling (2)
Metabolomics (2)
Multiomics (1)

Organisms

Homo sapiens (112)
Mus musculus (68)
Andropogon gerardi (23)
Bacteria (23)
Canis lupus familiaris (23)
Cnidaria (23)
Ensifer adhaerens (23)
Eukaryota (23)
Fasciola (23)
Hepatitis B virus (23)
Human alphaherpesvirus 1 strain 17 (23)
Human alphaherpesvirus 1 strain KOS (23)
Human betaherpesvirus 5 (23)
Human herpesvirus 2 strain 186 (23)
Madurella mycetomatis (23)
Mesocricetus auratus (23)
Miscanthus x giganteus (23)
Mus musculus (23)
Panicum virgatum (23)
Platyhelminthes (23)
Pseudomonas aeruginosa AES-1R (23)
Rattus norvegicus (23)
Rattus rattus (23)
Rhodococcus jostii RHA1 (23)
Rhodopseudomonas palustris (23)
Vesicular stomatitis virus (2)
Mesocricetus auratus (1)
Canis lupus familiaris (1)
Sindbis virus (1)
Canis lupus (1)

Organisms

Homo sapiens (66)
Mus musculus (61)
Human alphaherpesvirus 1 strain RH2 (1)
Sindbis virus (1)
Canis lupus (1)

Repository

ENA (162)
geo (130)
biostudies-arrayexpress (29)
pride (23)
BioModels (15)
iProX (5)
EGA (4)
MetaboLights (2)
ExpressionAtlas (1)
MassIVE (1)

Tissue

Cell culture (12)
Epithelial cell (5)
Brain (4)
Permanent cell line cell (3)
Colon (2)
Fibroblast (2)
Primary cell line cell (2)
Blood plasma (1)
Fibroblast of lung (1)
Liver (1)
Lymphocyte (1)
Peripheral blood mononuclear cell (1)

Disease

Glioblastoma (3)
Colon cancer (2)
Influenza (2)
Melanoma (2)
Skin cancer (1)
Cancer (1)
Breast cancer (1)
Metastatic prostate cancer (1)
Carcinoma (1)
Normal (1)
Breast Cancer (1)
Lung cancer, colorectal cancer etal (1)
Cancer (1)
Carcinoma, Squamous Cell (1)
Carcinoma (1)
Lung Neoplasms (1)
Colorectal Neoplasms (1)
Brain cancer (1)
Brain glioblastoma multiforme (1)
Fibrosarcoma (1)
Lung cancer (1)
Lymphoma (1)
Malignant neoplasm of ovary (1)
Pancreatic cancer (1)
Skin amelanotic melanoma (1)
Skin melanoma (1)

Technology Type

Mass Spectrometry (23)
Shotgun proteomics (13)
Affinity purification coupled with mass spectrometry proteomics (4)
Data-dependent acquisition (4)
Bottom-up proteomics (2)
Mass spectrometry assay (1)
Mass spectrometry (1)
HDMSE (1)

Instrument Platform

Illumina NovaSeq 6000 (2)
LTQ Orbitrap (1)
Liquid Chromatography MS - alternating - hilic (1)
Liquid Chromatography MS - alternating - reverse phase (1)
Liquid Chromatography MS - positive - reverse phase (1)
Liquid Chromatography MS - negative - reverse phase (1)

Publication Date

2025 (40)
2024 (30)
2026 (23)
2023 (22)
2022 (16)
2021 (9)
2019 (9)
2020 (7)
2016 (7)
2018 (6)
2013 (5)
2010 (5)
2014 (4)
2012 (4)
2015 (3)
2011 (3)
2009 (3)
2017 (3)
2008 (2)
2007 (2)

CHEBI ID

CHEBI:144829 (1)
CHEBI:34671 (1)
CHEBI:79877 (1)

Metabolite Name

Aminovaleric acid betaine (1)
4-hydroxystradiol (1)
1-Carboxyethylleucine (1)
11Z-Octadecenylcarnitine (1)
25,26-dihydroxyvitamin D (1)
2-Hydroxyhexadecanoylcarnitine (1)
Docosapentaenoic acid (22n-6) (1)
Hepoxilin A3 (1)
Docosapentaenoic acid (22n-3) (1)
21-Deoxycortisol (1)
Sulfolithocholylglycine (1)
N-Lactoylleucine (1)
Nirvanol (1)
3-Hydroxymethylantipyrine (1)
D-Tryptophan (1)
Cervonoyl ethanolamide (1)
24,25-Dihydroxyvitamin D (1)
Leukotriene B4 (1)
Adrenoyl ethanolamide (1)
Allopurinol (1)
Eplerenone (1)
Nabilone (1)
Pregabalin (1)
Corticosterone (1)
4-Hydroxyantipyrine (1)
Ethotoin (1)
Paricalcitol (1)
Trihexyphenidyl (1)
Retapamulin (1)
Prostaglandin A1 (1)

First Public Date

2026 (30)
2023 (28)
2025 (27)
2024 (23)
2022 (18)
2014 (8)
2019 (7)
2021 (6)
2020 (5)
2018 (5)
2017 (4)
2016 (1)

Modelling Approach

Ordinary differential equation model (12)
Delayed differential equation model (2)

Study status

Recruiting (3)
Terminated (1)
Active, not recruiting (1)
Not yet recruiting (1)
Completed (1)

Lab affiliation

Hubei University of Technology (2)
Sun Yat-sen University (2)
The Institute of Cancer Research (2)
The Institute of Cancer Research, London (2)
1. Translational Immunology Research Program, Transplantation Laboratory, University of Helsinki, Helsinki, Finland. 2. HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland (1)
Berlin Institute for Medical System Biology @ Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association Hannoversche Str. 28, 10115 Berlin Germanyt (1)
Cambridge Institute for Medical Research, University of Cambridge, Hills Road, Cambridge, CB2 0XY, UK (1)
Core Unit Proteomics, Berlin Institute of Health at Charite - Universitaetsmedizin Berlin and Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany (1)
Dep. of Oncology-Pathology, Karolinska Institutet, Scilifelab, Stockholm, Sweden (1)
Department of Immunology, Interfaculty Institute for Cell Biology, Tübingen, Germany (1)
Department of Pathology, Dalhousie University (1)
Department of Pathology, UAMS, Little Rock, AR, USA 2 The Winthrop P. Rockefeller Cancer Institute, UAMS, Little Rock, AR, USA (1)
Department of Pharmacology and Toxicology (1)
Departments of Pathology, Microbiology & Immunology, and Biology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada (1)
Laboratory of Physical and Chemical Methods for Structure Analysis, V.L. Talrose Institute for Energy Problems of Chemical Physics, N.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences, Moscow, Russia (1)
Pediatric Infectious Diseases Molecular Genetics and Microbiology Stony Brook University Life Sciences Building, Rm. 158 Stony Brook, NY 11794-5222 U.S.A. (1)
V.L. Talrose Institute for Energy Problems of Chemical Physics, N.N. Semenov Federal Research Center of Chemical Physics RAS (1)
laboratory of Physical and Chemical Methods for Structure Analysis, V.L. Talrose Institute for Energy Problems of Chemical Physics, N.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences, Moscow, Russia (1)
sun yat-sen university (1)

Keyword

Herpes simplex virus type 1 (2)
Oncolytic virus (2)
Immunotherapy (2)
LOAd703 (1)
Oncolytic Vaccinia Virus (1)
Tumor Cell Death (1)
Viral Therapy (1)
Anti-Tumor Immunity (1)
Human Epidermal Growth Factor Receptor 2 (1)
Salivary Gland (1)
Breast (1)
Tremelimumab (1)
Lung (1)
Esophageal (1)
Pancreatic (1)
Colorectal (1)
Gastric (1)
Bladder (1)
Durvalumab (1)
Pembrolizumab (1)
HER2 (1)

IsPrivate

False (15)

Submitter Keywords

Immuno-oncology (9)
Oncology (2)

Classification

viruses (2)

Study type

Transcription profiling by array (25)
Interventional (7)
RNA-seq of coding RNA (3)
Genotyping by array (1)

Release Date

2023 (186)
2021 (179)
2022 (168)
2020 (161)
2024 (152)
2025 (142)
2019 (113)
2018 (105)
2017 (103)
2016 (89)
2015 (82)
2014 (57)
2013 (46)
2012 (43)
2011 (30)
2010 (28)
2026 (15)
2009 (14)
2008 (12)
2006 (8)
2007 (4)
2001 (1)

Location

China (3)
United States (3)
Sweden (1)
Canada (1)

Previous page
1 / 209
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 209
Next page

Sort by:

Relevance

Page size

Lactobacillus acidophilus potentiates oncolytic virotherapy through modulating gut microbiota homeostasis in hepatocellular carcinoma

Oncolytic viruses (OVs) hold promise for cancer treatment. However, the antitumor efficacy is limited. Microbiota plays a pivotal role in cancer treatment and its impact on oncolytic virotherapy is unknown. Here, we show that VSVΔ51 has higher antitumor efficacy for hepatocellular carcinoma in the a...

2025-03-14 | MTBLS12297 | MetaboLights

Engineered Oncolytic VSV Enhances Tumor Killing in HBV-Positive HCC

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, with chronic hepatitis B virus (HBV) infection being a major contributor to its development. Despite this, effective treatment for HBV-associated HCC remains a significant challenge. In this study, we combined the s...

2025-07-17 | MTBLS12196 | MetaboLights

Resistance of primary ovarian cancer cells to oncolytic adenoviruses

This SuperSeries is composed of the following subset Series: GSE15350: Resistance of primary ovarian cancer cells to oncolytic adenoviruses part1 of 2 GSE15351: Resistance of primary ovarian cancer cells to oncolytic adenoviruses part2 of 2 Refer to individual Series

ORGANISM(S): Homo sapiens

2009-04-01 | E-GEOD-15473 | biostudies-arrayexpress

Model based Rational Design of an Oncolytic Virus with Improved Therapeutic Potential

Oncolytic viruses are complex biological agents that interact at multiple levels with both tumor and normal tissues. Anti-viral pathways induced by interferon are known to play a critical role in determining tumor cell sensitivity and normal cell resistance to infection with oncolytic viruses. Here ...

ORGANISM(S): Homo sapiens

2013-06-01 | E-MTAB-1636 | biostudies-arrayexpress

Transcription profiling of mouse with human solid tumors eradicated with an intravenously injected light-emitting oncolytic Vaccinia virus

Previously we reported that a recombinant vaccinia virus (VACV) carrying a light-emitting fusion gene enters, replicates in, and reveals the locations of tumors in mice. A new recombinant VACV, GLV-1h68, as a simultaneous diagnostic and therapeutic agent, was constructed by inserting three expressio...

ORGANISM(S): Mus musculus

2008-06-16 | E-GEOD-8513 | biostudies-arrayexpress

Subclone of resistant CT26 murine tumor shows high sensitivity to VA7 virotherapy: A novel system to study innate immunity and antigen dominance in oncolytic immuno-virotherapy

Recently, attenuated Semliki Forest virus vector VA7 completely eliminated type I interferon (IFN) unresponsive human U87 glioma xenografts while IFN responsive mouse GL261 and CT-2A gliomas proved refractory to the oncolytic virotherapy. Here we describe in two clones of a well established Balb/c m...

ORGANISM(S): Mus musculus

2014-09-05 | E-GEOD-53001 | biostudies-arrayexpress

Oncolytic Reovirus mediates innate-driven SARS-CoV-2 elimination in the absence of cell toxicity

Interplay between type I interferon (IFN) driven innate responses and viral antagonism strongly influences SARS-CoV-2 transmission and the COVID-19 disease course. Hence, variant adaptation includes diminished induction of IFN stimulated genes (ISG) and/or evasion of their effector functions. Exogen...

ORGANISM(S): Homo sapiens

2026-04-15 | E-MTAB-16855 | biostudies-arrayexpress

Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68

Oncolytic viral therapy represents an alternative therapeutic strategy for the treatment of cancer. This therapy relies on efficient replication of virus in tumor cells in vivo with minimal or no replication in normal tissues. We recently described GLV-1h68 as a modified Vaccinia Virus (VACV) constr...

ORGANISM(S): Homo sapiens

2012-03-24 | E-GEOD-28472 | biostudies-arrayexpress

Jenner2018 - treatment of oncolytic virus

The paper describes a model of oncolytic virotherapy. Created by COPASI 4.26 (Build 213) This model is described in the article: Mathematical Modelling of the Interaction Between Cancer Cells and an Oncolytic Virus: Insights into the Effects of Treatment Protocols Adrianne L. Jenner, Chae-Ok Yun...

2024-09-02 | BIOMD0000000789 | BioModels

Almuallem2020 - Virus-macrophage-tumour interactions in oncolytic viral therapies

This mathematical model of the role of the innate immune responses generated by macrophages in the context of anti-tumour oncolytic viral therapies is described in the publication: Nada Almuallem, Dumitru Trucu, Raluca Eftimie. "Oncolytic viral therapies and the delicate balance between virus-macrop...

2024-09-02 | BIOMD0000001033 | BioModels

Immuno-oncology

Previous page
1 / 209
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 209
Next page

Sort by:

Relevance

Page size

2088 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

CHEBI ID

Metabolite Name

First Public Date

Modelling Approach

Study status

Lab affiliation

Tags

Keyword

IsPrivate

Submitter Keywords

Classification

Study type

Release Date

Location

OmicsDI is part of the ELIXIR infrastructure

Tweets